PD 138312 is a novel broad-spectrum 7-pyrrolidinyl fluoronaphthyridines with a cyclopropyl or a difluorophenyl substitution at the 1 positions, respectively. It has been demonstrated to have excellent in vitro activity against gram-positive organisms. This compound was evaluated for its in vivo potencies against acute systemic infections in mice and in a mouse pneumococcal pneumonia model. Most remarkable was its comparative median protective value against methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes. PD 138312 has excellent therapeutic potential against clinically important gram-positive pathogens when the drugs are administered both orally and parenterally. References: Shapiro MA, Dever JA, Joannides ET, Sesnie JC, Vanderroest SR. In vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother. 1995 Oct;39(10):2183-6. PubMed PMID: 8619563; PubMed Central PMCID: PMC162910. 2: Cohen MA, Yoder SL, Huband MD, Roland GE, Courtney CL. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob Agents Chemother. 1995 Sep;39(9):2123-7. PubMed PMID: 8540728; PubMed Central PMCID: PMC162893. 3: Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother. 1994 Feb;38(2):369-70. PubMed PMID: 8192468; PubMed Central PMCID: PMC284459. 4: Huband MD, Cohen MA, Meservey MA, Roland GE, Yoder SL, Dazer ME, Domagala JM. In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother. 1993 Dec;37(12):2563-70. PubMed PMID: 8109918; PubMed Central PMCID: PMC192739. 5: Sánchez-Hernández J, Manzanares MA, Gutiérrez Zufiaurre MN, Munoz Criado S, Munoz Bellido JL, García-Rodríguez JA. In vitro activity of eight fluoroquinolones against multiresistant Stenotrophomonas maltophilia. Rev Esp Quimioter. 1999 Sep;12(3):234-6. PubMed PMID: 10878514. 6: García-Rodríguez JA, García Sánchez JE, Trujillano I, García Sánchez E, García García MI, Fresnadillo MJ. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob Agents Chemother. 1995 May;39(5):1194-5. PubMed PMID: 7625815; PubMed Central PMCID: PMC162710. 7: Hagen SE, Domagala JM, Gracheck SJ, Sesnie JA, Stier MA, Suto MJ. Synthesis and antibacterial activity of new quinolones containing a 7-[3-(1-amino-1-methylethyl)-1-pyrrolidinyl] moiety. Gram-positive agents with excellent oral activity and low side-effect potential. J Med Chem. 1994 Mar 18;37(6):733-8. PubMed PMID: 8145222. 8: Cohen MA, Gage JW, Huband MD, Meservey MA, VanderRoest SR, Yoder SL. Efficacy of quinolones in preventing Staphylococcus aureus-induced abscess in mice. J Antimicrob Chemother. 1995 Sep;36(3):551-5. PubMed PMID: 8830021.

纯度：≥98%

CAS：107334-06-5